Communiqués LB Pharmaceuticals Inc

Actions

LBRX

US50180M1080

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 19/08/2026			Varia. 5j.	Varia. 1 janv.
48,94 ^USD	+0,35%		+7,84%	+119,86%

11/08	LB Pharmaceuticals Inc publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
11/08	LB Pharmaceuticals : réduction de la perte par action au deuxième trimestre	MT

Communiqués

11/08	LB Pharmaceuticals Inc.: Q2 Earnings Snapshot	AQ
11/08	LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
29/07	LB Pharmaceuticals Announces $150 Million Private Placement	AQ
22/07	LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia	AQ
10/07	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)	AQ
30/06	LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations	AQ
28/05	LB Pharmaceuticals to Participate in Upcoming June Investor Events	AQ
12/05	LB Pharmaceuticals Inc.: Q1 Earnings Snapshot	AQ
12/05	LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update	AQ
22/04	LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia	AQ
09/04	LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference	AQ
27/03	LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)	AQ
26/03	LB Pharmaceuticals Inc.: Q4 Earnings Snapshot	AQ
26/03	LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update	AQ
26/03	LB Pharmaceuticals Initiates Pivotal Phase 3 trial for LB-102 in Patients with Schizophrenia	AQ
25/03	LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia	AQ
09/03	LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors	AQ
04/03	LB Pharmaceuticals to Participate in Upcoming March Investor Events	AQ
27/02	Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments	PR
10/02	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)	AQ
05/02	LB Pharmaceuticals Announces $100.0 Million Private Placement	AQ
26/01	LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program	AQ
21/01	LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel	AQ
12/01	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)	AQ
06/01	LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture	AQ